Redx Pharma strengthens senior team

12 Sep 2014

Pioneering pharma company Redx has bolstered its senior team, appointing drug discovery expert Dr Richard Armer as Chief Scientific Officer and Phil Tottey as Chief Financial Officer.

Richard, who has worked for organisations including Pfizer, Organon and Oxagen, previously held the role of CSO at Lectus Therapeutics. After joining Redx Oncology in early-2012 as Head of Chemistry, he moved to become Head of Research in December 2013.

During his career Richard has developed a particular focus on drug development activity. He specialises in drug disposition and intellectual property and has successfully identified positive leads for new drugs across a range of therapeutic areas.

Chartered accountant Phil Tottey will bring significant financial and operational experience developed during a career spanning 34 years to his new role. He started his professional life with Grant Thornton in Liverpool, before developing a career which has spanned sectors including retail, construction and media.

He is experienced working with both high-profile global organisations including media giant Emap, and local businesses, having successfully set up his own business offering training and consultancy to local SMEs in 2003.

Phil joined Redx in 2013, initially as Financial Controller before becoming Group Operations Director in December that year.

Redx Pharma CEO, Dr Neil Murray, said: We’re delighted to make these appointments and further bolster our executive team. Phil and Richard both bring significant expertise and experience to the business and will continue to play an invaluable role in Redx’s ongoing growth and development.

Richard’s remarkable technical expertise and scientific leadership has been of great value to Redx Oncology. As a pioneering business working at the frontline of drug development, applying those skills across the Redx group means that Richard will be a great asset to the team.

Phil’s depth of experience across a range of sectors, coupled with his extensive capabilities are a formidable combination and we’re delighted to welcome him to his new position.